BioRem (CVE:BRM) Upgraded by Cormark to “Moderate Buy” Rating

Cormark upgraded shares of BioRem (CVE:BRM) to a moderate buy rating in a report issued on Tuesday,Zacks.com reports.

BioRem Trading Down 5.4 %

Shares of BioRem stock opened at C$2.95 on Tuesday. The firm’s 50-day moving average price is C$2.83 and its 200 day moving average price is C$2.41. BioRem has a twelve month low of C$0.95 and a twelve month high of C$3.39. The firm has a market capitalization of C$46.32 million, a PE ratio of 14.05 and a beta of 0.85. The company has a current ratio of 1.57, a quick ratio of 1.08 and a debt-to-equity ratio of 48.97.

Insider Buying and Selling at BioRem

In other news, Director Derek Webb sold 120,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of C$2.93, for a total value of C$351,600.00. Company insiders own 1.90% of the company’s stock.

BioRem Company Profile

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs.